Skip to main content

Table 2 Summary of selected studies (number of study)

From: Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review

   ACEIs (total 6) ARBs (total 33) ARBs Losartan (total 14) ARBs Irbesartan (total 18) ARBs Valsartan (total 1)
Data source Trial based 0 33 14 18 1
Literature based 6 0 0 0 0
Intervention and control group Comparing with placebo/conventional therapy 2 22 14 8 0
Comparing with other drugs 0 12 0 11 1
Comparing different strategies 4 10 0 10 0
Decision model Markov model 6 20 1 18 1
Weibull model 0 3 3 0 0
Regression method 0 10 10 0 0
Perspective Third party payer 4 33 14 18 1
Societal 2 0 0 0 0
CE results Cost-saving 5 32 13 18 1
Cost-neutral 0 1 1 0 0
Very cost-effective 1 0 0 0 0
Cost-effective 0 0 0 0 0
Not cost-effective 0 0 0 0 0